ReadoutIn window
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair — Abiraterone - Usual
Phase 3 primary completion: Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms.
- Date
- Nov 2026
- Type
- Readout
- Indication
- Prostate Cancer